ns like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients’ unique aesthetic goals with enhanced flexibility and precision.”



BILL ANDRIOPOULOS, PHD

VICE PRESIDENT OF MEDICAL AFFAIRS

GALDERMA U.S.














The approval is based on results from a pivotal clinical trial, confirming the clinical performance and safety of Restylane Lyft for chin enhancement.1,2The primary endpoint of the study was met, demonstrating its safety and effectiveness in improving chin projection three months after initial injection, with improvement sustained in the majority of patients through 12 months.1Additional results showed:1


Global aesthetic improvement, as assessed by both patients and investigators, remained consistently high throughout the stu
=*=*=*=*=*=
当前为第3/13页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页